Cytek Biosciences, Inc.
CTKB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 3.9% | 17.7% | 28.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 55.4% | 56.7% | 61.6% | 61.9% |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -5% | -2.3% | 5.8% | 7% |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | -3% | -6.3% | 1.6% | 2.3% |
| EPS Diluted | -0.046 | -0.09 | 0.019 | 0.033 |
| % Growth | 48.7% | -582.8% | -43.6% | – |
| Operating Cash Flow | $0 | $0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | $0 |